{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:15:08Z","timestamp":1783116908433,"version":"3.54.6"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-KH143167"],"award-info":[{"award-number":["RS-2023-KH143167"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128641","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:10:34Z","timestamp":1777565434000},"page":"128641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recombinant AcHERV-baculovirus vaccine elicits robust immune responses against human norovirus"],"prefix":"10.1016","volume":"83","author":[{"given":"Doyoung","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeondong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Won","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Bong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128641_bb0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.idc.2017.07.012","article-title":"Norovirus infection in older adults: epidemiology, risk factors, and opportunities for prevention and control","volume":"31","author":"Cardemil","year":"2017","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.vaccine.2026.128641_bb0010","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/infdis\/jis251","article-title":"Noroviruses: the perfect human pathogens?","volume":"205","author":"Hall","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128641_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12060590","article-title":"Noroviruses: evolutionary dynamics, epidemiology, pathogenesis, and vaccine advances-a comprehensive review","author":"Omatola","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128641_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142927","article-title":"Aetiology-specific estimates of the global and regional incidence and mortality of diarrhoeal diseases commonly transmitted through food","volume":"10","author":"Pires","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2026.128641_bb0025","doi-asserted-by":"crossref","first-page":"15558","DOI":"10.1038\/s41598-023-42622-z","article-title":"Two successive outbreaks of acute gastroenteritis due to norovirus GII.6 in a holiday camp house","volume":"13","author":"Alseda","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128641_bb0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/cid\/ciy167","article-title":"Estimating the hospital burden of norovirus-associated gastroenteritis in England and its opportunity costs for nonadmitted patients","volume":"67","author":"Sandmann","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128641_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02153-8","article-title":"Predicted norovirus resurgence in 2021-2022 due to the relaxation of nonpharmaceutical interventions associated with COVID-19 restrictions in England: a mathematical modeling study","volume":"19","author":"O\u2019Reilly","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.128641_bb0040","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jmv.27426","article-title":"Norovirus outbreak amid COVID-19 in the United Kingdom; priorities for achieving control","volume":"94","author":"Yasmin","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0045","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1016\/j.vaccine.2016.10.090","article-title":"Report from the World Health Organization\u2019s third product development for vaccines advisory committee (PDVAC) meeting, Geneva, 8-10th June 2016","volume":"37","author":"Giersing","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128641_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/v14122811","article-title":"Norovirus: an overview of virology and preventative measures","author":"Winder","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128641_bb0055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14760584.2020.1777860","article-title":"Recent advances in human norovirus research and implications for candidate vaccines","volume":"19","author":"Cates","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128641_bb0060","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/cid\/ciu120","article-title":"The state of norovirus vaccines","volume":"58","author":"Debbink","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128641_bb0065","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1099\/jgv.0.001318","article-title":"Updated classification of norovirus genogroups and genotypes","volume":"100","author":"Chhabra","year":"2019","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/viro.1993.1345","article-title":"Sequence and genomic organization of Norwalk virus","volume":"195","author":"Jiang","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.128641_bb0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/jcp.32.8.786","article-title":"Winter vomiting disease caused by calicivirus","volume":"32","author":"Cubitt","year":"1979","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105259","article-title":"Global prevalence of norovirus in cases of acute gastroenteritis from 1997 to 2021: an updated systematic review and meta-analysis","volume":"161","author":"Liao","year":"2021","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2026.128641_bb0085","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1038\/s41598-025-87719-9","article-title":"Genomic diversity and comparative phylogenomic analysis of genus norovirus","volume":"15","author":"Doh","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128641_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00884-2","article-title":"A narrative review of norovirus epidemiology, biology, and challenges to vaccine development","volume":"9","author":"Carlson","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128641_bb0095","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1016\/j.vaccine.2020.06.011","article-title":"A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose","volume":"38","author":"Treanor","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128641_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1021500","article-title":"A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine","volume":"13","author":"Leroux-Roels","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2450878","article-title":"Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: a phase 2, randomized, double-blind trial","volume":"21","author":"Saez-Llorens","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128641_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.906275","article-title":"6-valent virus-like particle-based vaccine induced potent and sustained immunity against noroviruses in mice","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41541-021-00303-w","article-title":"Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2","volume":"6","author":"Cho","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128641_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126355","article-title":"Delivery of SARS-CoV-2 spike and membrane genes in a single baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern","volume":"42","author":"Chun","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128641_bb0125","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.vaccine.2009.11.044","article-title":"Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1","volume":"28","author":"Lee","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128641_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-0934(01)00404-9","article-title":"Genogroup-specific PCR primers for detection of Norwalk-like viruses","volume":"100","author":"Kojima","year":"2002","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2026.128641_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12951-021-00772-0","article-title":"Modular vaccine platform based on the norovirus-like particle","volume":"19","author":"Lampinen","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0140","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/infdis\/jiad401","article-title":"A bivalent human norovirus vaccine induces homotypic and heterotypic neutralizing antibodies","volume":"229","author":"Atmar","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128641_bb0145","first-page":"739","article-title":"Comparison of microneutralization and Histo-blood group antigen-blocking assays for functional norovirus antibody detection","volume":"221","author":"Atmar","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128641_bb0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2407519121","article-title":"Receptor usage of syncytin-1: ASCT2, but not ASCT1, is a functional receptor and effector of cell fusion in the human placenta","volume":"121","author":"Stafl","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128641_bb0155","article-title":"Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2026.128641_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ads0556","article-title":"An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial","volume":"17","author":"Flitter","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128641_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001807","article-title":"Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial","volume":"12","author":"Lindesmith","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128641_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188431","article-title":"Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant","volume":"14","author":"Waerlop","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0175","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/CVI.00015-15","article-title":"Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition","volume":"22","author":"Malm","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0180","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/infdis\/jix385","article-title":"Emergence of novel human norovirus GII.17 strains correlates with changes in blockade antibody epitopes","volume":"216","author":"Lindesmith","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128641_bb0185","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1080\/22221751.2021.1925162","article-title":"Identification of a blockade epitope of human norovirus GII.17","volume":"10","author":"Yi","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2026.128641_bb0190","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1016\/j.vaccine.2020.07.069","article-title":"Efficacy of an intramuscular bivalent norovirus GI.1\/GII.4 virus-like particle vaccine candidate in healthy US adults","volume":"38","author":"Sherwood","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128641_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.epidem.2025.100842","article-title":"Projecting the population-level impact of norovirus vaccines","volume":"52","author":"Koelle","year":"2025","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2026.128641_bb0200","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jiaa116","article-title":"Genotype-specific neutralization of norovirus is mediated by antibodies against the protruding domain of the major capsid protein","volume":"225","author":"Ford-Siltz","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128641_bb0205","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/jmv.26474","article-title":"The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain","volume":"93","author":"Du","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.653719","article-title":"Evolutionary mechanism of immunological cross-reactivity between different GII.17 variants","volume":"12","author":"Zuo","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0215","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1016\/j.vaccine.2006.03.080","article-title":"Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains","volume":"24","author":"LoBue","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128641_bb0220","doi-asserted-by":"crossref","first-page":"14275","DOI":"10.1038\/s41598-022-18383-6","article-title":"Profiling of humoral immune responses to norovirus in children across Europe","volume":"12","author":"Villabruna","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128641_bb0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1073\/pnas.1014577107","article-title":"Chimpanzees as an animal model for human norovirus infection and vaccine development","volume":"108","author":"Bok","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128641_bb0230","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00938-23","article-title":"Chimeric virus-like particles of human norovirus constructed by structure-guided epitope grafting elicit cross-reactive immunity against both GI.1 and GII.4 genotypes","volume":"97","author":"Hou","year":"2023","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1900994","article-title":"Understanding the relationship between norovirus diversity and immunity","volume":"13","author":"Ford-Siltz","year":"2021","journal-title":"Gut Microbes"},{"key":"10.1016\/j.vaccine.2026.128641_bb0240","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1038\/s41467-021-24649-w","article-title":"Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses","volume":"12","author":"Alvarado","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128641_bb0245","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41541-024-00976-z","article-title":"Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection","volume":"9","author":"Atochina-Vasserman","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128641_bb0250","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4161\/hv.27147","article-title":"TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines","volume":"10","author":"Hjelm","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128641_bb0255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.mt.6300008","article-title":"Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein","volume":"15","author":"Strauss","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2026.128641_bb0260","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1517\/14712598.4.6.861","article-title":"Viral vectors for inducing CD8+ T cell responses","volume":"4","author":"Truckenmiller","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2026.128641_bb0265","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41385-021-00407-5","article-title":"IL-17 mediates protective immunity against nasal infection with bordetella pertussis by mobilizing neutrophils, especially Siglec-F(+) neutrophils","volume":"14","author":"Borkner","year":"2021","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2026.128641_bb0270","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gene.2017.01.016","article-title":"Interluekin-17A (IL17A)","volume":"614","author":"Chen","year":"2017","journal-title":"Gene"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:15:04Z","timestamp":1783113304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"alternative-id":["S0264410X26004494"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128641","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant AcHERV-baculovirus vaccine elicits robust immune responses against human norovirus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128641"}}